Eli Lilly raised its 2025 guidance to $60-62 billion and reported Q2 earnings surpassing estimates, driven by high demand for weight loss and diabetes drugs, including Mounjaro and Zepbound. Late-stage trial data on its obesity pill, orforglipron, showed promising results. CEO David Ricks remains optimistic despite shares dropping 12% premarket.

Q2 revenue reached $15.56 billion, up 38% from last year, with U.S. sales soaring 38% to $10.81 billion. Net income for the quarter was $5.66 billion, or $6.29 per share, compared to $2.97 billion, or $3.28 per share, a year ago. Adjusted earnings per share were $6.31, beating Wall Street expectations.

President Trump’s existing tariffs were factored into Eli Lilly’s guidance but not his planned levies on pharmaceutical imports. The company faces pressure to lower drug prices amid the president’s efforts to slash costs by tying U.S. drug prices to lower ones abroad. Eli Lilly remains optimistic about its future pipeline and growth.

Read more at CNBC: Eli Lilly (LLY) Q2 2025 earnings report